In patients receiving foecal microbiota transplantation (FMT) for the treatment of Clostridium difficile infection (CDI), high levels of Candida albicans may be associated with poor outcomes, a recent study has shown.
MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.
MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.
MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.
The factor Xa inhibitor rivaroxaban failed in reducing the risk of death, MI or stroke as compared with placebo among patients with worsening chronic heart failure (HF) and underlying coronary artery disease (CAD) without atrial fibrillation (AF), according to results of the COMMANDER HF trial reported at the European Society of Cardiology (ESC) Congress 2018.
Lorcaserin has become the first weight-loss agent to show cardiovascular (CV) safety in patients at high CV risk, according to results of the CAMELLIA–TIMI 61 study presented at the European Society of Cardiology (ESC) Congress 2018.
The combination of dolutegravir + lamivudine appeared noninferior to dolutegravir + tenofovir/emtricitabine in reducing viral load in treatment-naïve patients with HIV-1 infection, according to the phase III GEMINI-1 and GEMINI-2* trials presented at AIDS 2018.